ATE203751T1 - K-252a derivate, die neurotrophin-induzierte aktivität erhöhen - Google Patents

K-252a derivate, die neurotrophin-induzierte aktivität erhöhen

Info

Publication number
ATE203751T1
ATE203751T1 AT94929228T AT94929228T ATE203751T1 AT E203751 T1 ATE203751 T1 AT E203751T1 AT 94929228 T AT94929228 T AT 94929228T AT 94929228 T AT94929228 T AT 94929228T AT E203751 T1 ATE203751 T1 AT E203751T1
Authority
AT
Austria
Prior art keywords
derivatives
induced activity
neurotrophin
increase
increase neurotrophin
Prior art date
Application number
AT94929228T
Other languages
English (en)
Inventor
Marcie A Glicksman
David P Rotella
Nicola Neff
Chikara Murakata
Robert L Hudkins
Original Assignee
Cephalon Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Kyowa Hakko Kogyo Kk filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE203751T1 publication Critical patent/ATE203751T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT94929228T 1993-09-16 1994-09-16 K-252a derivate, die neurotrophin-induzierte aktivität erhöhen ATE203751T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/122,893 US5468872A (en) 1993-09-16 1993-09-16 K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
PCT/US1994/010495 WO1995007911A1 (en) 1993-09-16 1994-09-16 K-252a DERIVATIVES WHICH ENHANCE NEUROTROPHIN-INDUCED ACTIVITY

Publications (1)

Publication Number Publication Date
ATE203751T1 true ATE203751T1 (de) 2001-08-15

Family

ID=22405467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929228T ATE203751T1 (de) 1993-09-16 1994-09-16 K-252a derivate, die neurotrophin-induzierte aktivität erhöhen

Country Status (14)

Country Link
US (2) US5468872A (de)
EP (1) EP0719268B1 (de)
JP (2) JP3943126B2 (de)
KR (1) KR100186912B1 (de)
AT (1) ATE203751T1 (de)
AU (1) AU693480B2 (de)
CA (1) CA2171561C (de)
DE (1) DE69427862T2 (de)
ES (1) ES2160637T3 (de)
FI (1) FI961236A7 (de)
HU (1) HU222570B1 (de)
NO (1) NO309228B1 (de)
NZ (2) NZ274355A (de)
WO (1) WO1995007911A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505124A (ja) * 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
EP0675125A1 (de) * 1994-03-18 1995-10-04 Kyowa Hakko Kogyo Co., Ltd. Therapeutisches Mittel für Thrombozytopenie und Indolocarbazol-Derivate
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
AU6733996A (en) * 1995-07-31 1997-02-26 Ciba-Geigy Ag Staurosporine analogues
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
DE69812177T2 (de) 1997-12-31 2004-01-15 Cephalon Inc 3'-epi k-252a derivate
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1126855B1 (de) * 1998-09-25 2007-05-09 Cephalon, Inc. Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
WO2000075662A1 (en) * 1999-06-09 2000-12-14 Ljl Biosystems, Inc. Cell-signaling assays
US6472385B1 (en) * 1999-08-09 2002-10-29 Trustees Of Darmouth College Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
FR2798931B1 (fr) * 1999-09-22 2001-11-16 Oreal Nouveaux composes indoliques, leur utilisation pour la teinture et le maquillage des matieres keratiniques, compositions les contenant et procedes de teinture
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6555677B2 (en) 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
RU2003131269A (ru) 2001-03-22 2005-05-10 Бристол-Маерс Сквибб Компани (Us) Производные индолопирролокарбазолов и сахаров, цитотоксические и селективные по отношению к топоизомеразе i
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US20040186044A1 (en) * 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
EP1891966B1 (de) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation der Neurotrophinaktivität;Screeningsverfahren
CA2519227C (en) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Nogo receptor binding protein
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2068866A4 (de) * 2006-07-24 2010-04-07 Biogen Idec Inc Verfahren zur förderung von myelinisierung, neuronalem überleben und oligodendrozytendifferenzierung mittels verabreichung von sp35- bzw. trka-antagonisten
RS60019B1 (sr) * 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
ES2326459B1 (es) 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
NZ593438A (en) * 2008-12-22 2012-12-21 Creabilis S A Synthesis of polymer conjugates of indolocarbazole compounds
CN103242404A (zh) * 2012-02-03 2013-08-14 复旦大学 N-鼠李糖基苯并咔唑化合物及其合成方法和在制药中的用途
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
CN103012417B (zh) * 2013-01-08 2015-01-07 中国科学院昆明植物研究所 黄皮属植物中的咔唑生物碱,以其为抗肿瘤活性成分的药物组合物,其制备方法和应用
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60257652A (ja) * 1984-06-02 1985-12-19 Canon Inc 画像処理装置
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5231001A (en) * 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
IE921315A1 (en) * 1991-07-03 1993-01-13 Regeneron Pharma Method and assay system for neurothrophin activity
JPH07505124A (ja) * 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
JPH05247056A (ja) * 1992-03-03 1993-09-24 Kyowa Hakko Kogyo Co Ltd インドロカルバゾール誘導体
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
DE4217963A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Verwendung von Indolocarbazolen zur Behandlung von AIDS
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders

Also Published As

Publication number Publication date
WO1995007911A1 (en) 1995-03-23
FI961236L (fi) 1996-03-15
JP2005220141A (ja) 2005-08-18
HU222570B1 (hu) 2003-08-28
NO309228B1 (no) 2001-01-02
NO961087L (no) 1996-05-13
DE69427862D1 (de) 2001-09-06
KR100186912B1 (ko) 1999-05-01
AU693480B2 (en) 1998-07-02
AU7836394A (en) 1995-04-03
KR960704894A (ko) 1996-10-09
FI961236A0 (fi) 1996-03-15
JP3943126B2 (ja) 2007-07-11
JPH09502730A (ja) 1997-03-18
HUT74679A (en) 1997-01-28
EP0719268B1 (de) 2001-08-01
US5516772A (en) 1996-05-14
DE69427862T2 (de) 2002-04-11
HU9600657D0 (en) 1996-05-28
ES2160637T3 (es) 2001-11-16
CA2171561A1 (en) 1995-03-23
CA2171561C (en) 1999-08-03
NZ314037A (en) 2000-09-29
FI961236A7 (fi) 1996-03-15
NZ274355A (en) 1997-03-24
NO961087D0 (no) 1996-03-15
EP0719268A1 (de) 1996-07-03
US5468872A (en) 1995-11-21

Similar Documents

Publication Publication Date Title
DE69427862D1 (de) K-252a derivate, die neurotrophin-induzierte aktivität erhöhen
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
NO932954L (no) 2,4-diaminokinazolin-derivater for aa oppnaa oeket antitumoraktivitet
FI955911A7 (fi) Pyratsolopyrimidinonit impotenssin hoidossa
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
NO302573B1 (no) Nye merkaptodiazepinderivater som er anvendbare som inhibitorer av enkefalinase og ACE
ATE213245T1 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
BR9707659A (pt) Pirrol(2,3-C) carbarzol-6-onas que potencializam atividade atividade de interferon gama
GR3006073T3 (de)
AU586677B2 (en) 2,3,4,5-tetrahydrobenzazepines useful in the treatment of mental disorders
TW282455B (de)
FI954775L (fi) Uusia polysyklisiä yhdisteitä ja niiden johdoksia neurotransmittereiden vapautumista edistävinä aineina, jotka ovat käyttökelpoisia kognitiivisten häiriöiden hoidossa
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
DK0391185T3 (da) 1,8-Naphthyridiner
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
AU7025087A (en) Pharmaceutical compositions for the therapy of cerebropathies on functional and organic base
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DE69202895D1 (de) Feuchtmittelzusatz und Anwendung desselben.
MX9307679A (es) Derivados de furanona utiles en terapia.
FR2697253B1 (fr) Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique.
ZA893606B (en) Use of diazepinones for treating disorders of the microcirculation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties